Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Cancer
- Conditions
- First Posted Date
- 2005-01-05
- Last Posted Date
- 2011-07-04
- Lead Sponsor
- INSYS Therapeutics Inc
- Target Recruit Count
- 40
- Registration Number
- NCT00100672
- Locations
- ๐บ๐ธ
premiere Oncology-Arizona, Scottsdale, Arizona, United States
๐บ๐ธPremiere Oncology-Santa Monica, Santa Monica, California, United States
Comparison of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) and Taxolยฎ Pharmacokinetics in Patients With Advanced Cancer
- Conditions
- First Posted Date
- 2004-12-24
- Last Posted Date
- 2011-07-04
- Lead Sponsor
- INSYS Therapeutics Inc
- Target Recruit Count
- 48
- Registration Number
- NCT00100139
- Locations
- ๐บ๐ธ
Cancer Institute of New Jersey - University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, United States
๐ฉ๐ชAllgemeines Krankenhaus St. Georg, Hamburg, Germany
๐ฉ๐ชUniversitatsklinikum Essen, Essen, Germany
IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma
- Conditions
- First Posted Date
- 2004-08-06
- Last Posted Date
- 2011-07-04
- Lead Sponsor
- INSYS Therapeutics Inc
- Target Recruit Count
- 24
- Registration Number
- NCT00089427
- Locations
- ๐บ๐ธ
Duke University Medical Center, Durham, North Carolina, United States
๐บ๐ธUniversity of California San Francisco - Dept. of Neurological Surgery, San Francisco, California, United States
๐บ๐ธCarolina Neurosurgery & Spine Assoc., Charlotte, North Carolina, United States
Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients With Advanced Cancer
- Conditions
- First Posted Date
- 2004-04-02
- Last Posted Date
- 2011-07-04
- Lead Sponsor
- INSYS Therapeutics Inc
- Target Recruit Count
- 40
- Registration Number
- NCT00080418
- Locations
- ๐บ๐ธ
Cancer Institute of New Jersey - University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, United States
๐บ๐ธFox Chase Temple Cancer Center - Temple University, Philadelphia, Pennsylvania, United States
๐บ๐ธH. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme
- Conditions
- First Posted Date
- 2004-02-10
- Last Posted Date
- 2011-06-06
- Lead Sponsor
- INSYS Therapeutics Inc
- Target Recruit Count
- 300
- Registration Number
- NCT00076986
- Locations
- ๐บ๐ธ
City of Hope National Medical Center, Duarte, California, United States
๐บ๐ธUniversity of California - Los Angeles Neuro-Oncology Program, Los Angeles, California, United States
๐บ๐ธSt. Louis University, St. Louis, Missouri, United States
Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma
- First Posted Date
- 2003-07-15
- Last Posted Date
- 2011-06-06
- Lead Sponsor
- INSYS Therapeutics Inc
- Target Recruit Count
- 18
- Registration Number
- NCT00064779
- Locations
- ๐บ๐ธ
Duke University Medical Center, Durham, North Carolina, United States
Liposome Encapsulated SN38 (LE-SN38) in Patients With Advanced Cancer
- Conditions
- First Posted Date
- 2002-10-02
- Last Posted Date
- 2011-07-04
- Lead Sponsor
- INSYS Therapeutics Inc
- Target Recruit Count
- 40
- Registration Number
- NCT00046540
- Locations
- ๐บ๐ธ
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
๐บ๐ธBarbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
๐บ๐ธThe Ohio State University, Columbus, Ohio, United States
Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma
- Conditions
- First Posted Date
- 2002-07-12
- Last Posted Date
- 2011-06-06
- Lead Sponsor
- INSYS Therapeutics Inc
- Target Recruit Count
- 80
- Registration Number
- NCT00041587
- Locations
- ๐ฎ๐ฑ
Sourasky Medical Center, Tel Aviv, Israel
๐ฉ๐ชUniversity Hospital Kiel, Department of Neurosurgery, Kiel, Germany
๐บ๐ธCleveland Clinic Foundation, Cleveland, Ohio, United States
Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion for 10 Days
- Conditions
- First Posted Date
- 2001-09-25
- Last Posted Date
- 2014-11-14
- Lead Sponsor
- INSYS Therapeutics Inc
- Registration Number
- NCT00024674
- Locations
- ๐บ๐ธ
NCI/NIH, Bethesda, Maryland, United States
Study to Determine Maximum Tolerated Dose of LErafAON Combined With Radiotherapy in Patients With Advanced Malignancies
- Conditions
- First Posted Date
- 2001-09-25
- Last Posted Date
- 2011-04-13
- Lead Sponsor
- INSYS Therapeutics Inc
- Target Recruit Count
- 25
- Registration Number
- NCT00024648
- Locations
- ๐บ๐ธ
Georgetown University, Washington, District of Columbia, United States
๐บ๐ธFox Chase Cancer Center, Philadelphia, Pennsylvania, United States
๐บ๐ธTemple University Cancer Center, Philadelphia, Pennsylvania, United States